Nicox SA - Stock Price History | NICXF

Historical daily share price chart and data for Nicox SA since 1969 adjusted for splits. The latest closing stock price for Nicox SA as of December 31, 1969 is 0.00.
  • The all-time high Nicox SA stock closing price was 0.00 on December 31, 1969.
  • The Nicox SA 52-week high stock price is 0.00, which is NAN% above the current share price.
  • The Nicox SA 52-week low stock price is 0.00, which is NAN% below the current share price.
  • The average Nicox SA stock price for the last 52 weeks is NaN.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Nicox SA Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.142B $0.016B
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. By leveraging their proprietary expertise in nitric oxide (NO) donation and other technologies, they are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Their portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on their proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis. Their research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71